Effects of chemotherapy combined with Chinese herbal medicine Kangliu Zengxiao Decoction on tumor markers of patients with advanced non- small-cell lung cancer: A randomized, controlled trial

Journal of Chinese Integrative Medicine

Volumn 9, Issue 5, 2011, Pages 525-530

  Yan, Gui Ying ^a   Xu, Zhen Ye ^b   Deng, Hai Bin ^b   Wan, Zhi Yong ^a   Zhang, Lei ^a   Zhu, Jiao Yu ^c  

^a SHANGHAI PUNAN HOSPITAL   (China)

^b SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^c China swzlym onlineshcn   (China)

Author keywords

Antigen; Antineoplastic combined chemotherapy protocols; Biological; Carbohydrate; Carcinoma; Chinese herbal; Drugs; Non small cell lung; Prospective study; Randomized controlled trial; Tumor markers; Tumor related

Indexed keywords

CARBOHYDRATE ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CHINESE DRUG; CISPLATIN; CYTOKERATIN 19 FRAGMENT; KANGLIU ZENGXIAO; NAVELBINE; UNCLASSIFIED DRUG;

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER REGRESSION; CONTROLLED STUDY; DISEASE CONTROL; DRUG EFFICACY; HUMAN; KARNOFSKY PERFORMANCE STATUS; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SYMPTOM; TREATMENT RESPONSE; TUMOR VOLUME;

ADOLESCENT; ADULT; AGED; ANTIGENS, NEOPLASM; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DRUGS, CHINESE HERBAL; FEMALE; HUMANS; KERATIN-19; LUNG NEOPLASMS; MALE; MIDDLE AGED; PHYTOTHERAPY; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; VINBLASTINE; YOUNG ADULT;

EID: 79959359256     PISSN: 16721977     EISSN: None     Source Type: Journal    
DOI: 10.3736/jcim20110509     Document Type: Article

References (14)

1. Li CH. Strengthen the establishment and evaluation of tumor makers. Zhonghua Jian Yan Yi Xue Za Zhi. 2000; 23(1): 6-8.
2. Chen W, Sun YL, Xi Y. Correlation between serum tumor marker level and stage, therapeutic response and survival in patients with lung cancer. Biao Ji Mian Yi Fen Xi Yu Lin Chuang. 2008; 15 (4): 209-211, 221. Chinese with abstract in English.
3. Le Cesne A, Arriagada R, Grunenwald D, Baldeyrou P, Girard P, Bretel JJ, Le Chevalier T. New therapeutic strategies and current research in inoperable locally advanced non-small-cell lung cancers (stage III B). Bull Cancer. 1997; 84(4): 413-419.
4. Xu ZY, Yang YF. Integrated traditional Chinese and Western medicine in lung cancer. Beijing: People's Medical Publishing House. 2002: 451-456, 815-816.
5. Zheng XY. Guidelines for clinical research on Chinese herbal medicines (trail implementation). Beijing: China Medical Science Press. 2002: 216-221. Chinese.
6. Zha RJ, He CQ, Zeng DW, Huang XM. Diagnosis and treatment of lung cancer in modern times. 2nd ed. Beijing: People's Military Medical Press. 1999: 414-417. Chinese.
7. Shi YH, Lu XL. Application of serum CA-50 in diagnosis and treatment of tumor. Jiangsu Yi Yao. 1998; 24(2): 139. Chinese.
8. Xue QP, Qiu XH, Yang MN. Application of serum tumor specific growth factor, CA-50 and CA19-9 in diagnosis. Nanjing Yi Ke Da Xue Xue Bao Zi Ran Ke Xue Ban. 2001; 21(3): 270-271. Chinese.
9. Hatzakis KD, Froudarakis ME, Bouros D, Tzanakis N, Karkavitsas N, Siafakas NM. Prognostic value of serum tumor markers in patients with lung cancer. Respiration. 2002; 69(1): 25-29.
10. Li H, Wan ZF. Clinical value of combined determination of serum CEA and CYFRA21-1 levels for diagnosis of NSCLC. Fang She Mian Yi Xue Za Zhi. 2006; 19 (5): 432-433. Chinese with abstract in English.
11. Carpelan-Holmström M, Louhimo J, Stenman UH, Alfthan H, Järvinen H, Haglund C. CEA, CA 242, CA 19-9, CA 72-4 and hCGbeta in the diagnosis of recurrent colorectal cancer. Tumour Biol. 2004; 25(5-6): 228-234.
12. Foa P, Fornier M, Miceli R, Seregni E, Santambrogio L, Nosotti M, Cataldo I, Sala M, Caldiera S, Bombardieri E. Tumour markers CEA, NSE, SCC, TP A and CYFRA 21.1 in resectable non-small cell lung cancer. Anticancer Res. 1999; 19(4C): 3613-3618.
13. Du TX, Wang ZZ, Tian R. Changes of NSE, CYFRA2l-l and CEA observed by RIA in patients with lung tumor. Zhong Liu Fang Zhi Yan Jiu. 2000; 27 (3): 172-174. Chinese.
14. Gao WH, Zhao XD, Zhou CC. Application value of serum tumour markers in chemotherapy for non-small-cell lung cancer. Lin Chuang Fei Ke Za Zhi. 2002; 7 (2): 41-42. Chinese.